ES2161201T1 - Derivado de benzamida, composiciones que contienen dicho derivado y su empleo. - Google Patents

Derivado de benzamida, composiciones que contienen dicho derivado y su empleo.

Info

Publication number
ES2161201T1
ES2161201T1 ES95917310T ES95917310T ES2161201T1 ES 2161201 T1 ES2161201 T1 ES 2161201T1 ES 95917310 T ES95917310 T ES 95917310T ES 95917310 T ES95917310 T ES 95917310T ES 2161201 T1 ES2161201 T1 ES 2161201T1
Authority
ES
Spain
Prior art keywords
derivative
sub
benzamida
employment
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES95917310T
Other languages
English (en)
Other versions
ES2161201T3 (es
Inventor
Jean Francois Rossignol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Romark Laboratories LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2161201(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/227,033 external-priority patent/US5387598A/en
Priority claimed from US08/301,407 external-priority patent/US5578621A/en
Application filed by Romark Laboratories LC filed Critical Romark Laboratories LC
Publication of ES2161201T1 publication Critical patent/ES2161201T1/es
Application granted granted Critical
Publication of ES2161201T3 publication Critical patent/ES2161201T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS DE FORMULA (I) EN LOS QUE UNO DE LOS SIMBOLOS R{SUB,1}, R{SUB,2}, R{SUB,3}, R{SUB,4} Y R{SUB,5} REPRESENTA OH, MIENTRAS QUE LOS SIMBOLOS RESTANTES SON H; A UNA COMPOSICION FARMACEUTICA QUE CONTENGA DICHO COMPUESTO, Y AL USO DE DICHO COMPUESTO COMO AGENTE ANTIPARASITOS, ANTI-BACTERIAS, ANTI-FUNGICO, ANTI-VIRAL
ES95917310T 1994-04-13 1995-04-11 Derivados de benzamida, composiciones que contienen dichos derivados ysu empleo. Expired - Lifetime ES2161201T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/227,033 US5387598A (en) 1994-04-13 1994-04-13 Composition and galenic formulation suitable for combatting affections of the lower abdomen
US08/301,407 US5578621A (en) 1994-09-08 1994-09-08 Benzamide derivatives
US38385595A 1995-02-06 1995-02-06

Publications (2)

Publication Number Publication Date
ES2161201T1 true ES2161201T1 (es) 2001-12-01
ES2161201T3 ES2161201T3 (es) 2002-12-01

Family

ID=27397680

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95917310T Expired - Lifetime ES2161201T3 (es) 1994-04-13 1995-04-11 Derivados de benzamida, composiciones que contienen dichos derivados ysu empleo.

Country Status (24)

Country Link
EP (1) EP0755386B1 (es)
JP (1) JP3224395B2 (es)
KR (2) KR100348440B1 (es)
CN (1) CN1072654C (es)
AP (1) AP645A (es)
AT (1) ATE218557T1 (es)
AU (1) AU689582B2 (es)
BG (1) BG62932B1 (es)
BR (1) BR9507371A (es)
CA (1) CA2187110C (es)
CZ (1) CZ287002B6 (es)
DE (1) DE69526936T2 (es)
DK (1) DK0755386T3 (es)
ES (1) ES2161201T3 (es)
FI (1) FI120258B (es)
HU (1) HUT77404A (es)
NZ (1) NZ284800A (es)
OA (1) OA10463A (es)
PL (1) PL186504B1 (es)
PT (1) PT755386E (es)
RU (1) RU2140915C1 (es)
SI (1) SI0755386T1 (es)
SK (1) SK281949B6 (es)
WO (1) WO1995028393A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856348A (en) * 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
US8828727B2 (en) 2004-07-21 2014-09-09 Dana-Farber Cancer Institute Lentiviral vectors and uses thereof
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
ES2422556T3 (es) 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
CA2695517C (en) 2007-08-03 2016-09-20 J. Edward Semple Alkylsulfonyl-substituted thiazolide compounds
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
JP5932640B2 (ja) 2009-06-26 2016-06-08 ロマーク ラボラトリーズ エル．シー． インフルエンザを治療するための化合物および方法
US8999360B2 (en) * 2009-10-22 2015-04-07 Thomas Julius Borody Compositions and methods for treating extracellular parasitic infections
CN104094927B (zh) * 2013-04-02 2016-06-01 兴邦（武汉）生物科技有限公司 一种处理植物的助剂组合物
TW201630606A (zh) * 2015-01-21 2016-09-01 諾華公司 包含局部藥物之蓋崙（ｇａｌｅｎｉｃ）調配物
CA3087898A1 (en) 2018-02-02 2019-08-08 Ripple Therapeutics Corporation Glass formulations comprising steroid dimers and uses thereof
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
CA3219500A1 (en) * 2021-05-28 2022-12-01 Theodore HENDERSON Treatment using an antiviral compound and nitazoxanide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1306603A (fr) * 1958-08-14 1962-10-19 Innothera Lab Sa Dérivés thiazoliques et leur procédé de préparation
FR716M (es) * 1960-08-05 1961-08-07
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
FR2435905A1 (fr) * 1978-09-13 1980-04-11 Anvar Nouveaux agents molluscicides derives du benzamido-2 nitro-5 thiazole
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US4447414A (en) * 1982-12-21 1984-05-08 Cutter Laboratories, Inc. Carnivore anthelmintics

Also Published As

Publication number Publication date
KR100373081B1 (ko) 2003-02-25
SK130796A3 (en) 1997-06-04
ES2161201T3 (es) 2002-12-01
AP9600866A0 (en) 1996-10-31
NZ284800A (en) 1998-02-26
ATE218557T1 (de) 2002-06-15
SK281949B6 (sk) 2001-09-11
HU9602798D0 (en) 1996-12-30
JPH09511997A (ja) 1997-12-02
KR100348440B1 (ko) 2002-11-29
CN1072654C (zh) 2001-10-10
EP0755386A1 (en) 1997-01-29
DK0755386T3 (da) 2002-08-26
PL186504B1 (pl) 2004-01-30
PL316757A1 (en) 1997-02-03
AU2344095A (en) 1995-11-10
OA10463A (en) 2002-04-03
BR9507371A (pt) 1997-09-23
AU689582B2 (en) 1998-04-02
BG62932B1 (bg) 2000-11-30
CA2187110C (en) 2002-03-19
DE69526936T2 (de) 2003-02-20
SI0755386T1 (en) 2002-10-31
CA2187110A1 (en) 1995-10-26
PT755386E (pt) 2002-11-29
CN1145621A (zh) 1997-03-19
CZ287002B6 (en) 2000-08-16
DE69526936D1 (de) 2002-07-11
CZ295996A3 (en) 1997-03-12
EP0755386B1 (en) 2002-06-05
FI964031A (fi) 1996-10-08
AP645A (en) 1998-04-24
FI964031A0 (fi) 1996-10-08
HUT77404A (hu) 1998-04-28
RU2140915C1 (ru) 1999-11-10
FI120258B (fi) 2009-08-31
WO1995028393A1 (en) 1995-10-26
BG100884A (en) 1997-07-31
JP3224395B2 (ja) 2001-10-29

Similar Documents

Publication Publication Date Title
ES2161201T1 (es) Derivado de benzamida, composiciones que contienen dicho derivado y su empleo.
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
ES2168737T3 (es) Inhibidores de la oxido nitrico sintasa.
FI931031A (fi) Mometasonfuroatmonohydrat, foerfarande foer dess framstaellning och farmaceutiska sammansaettningar
CL2004001128A1 (es) Compuestos derivados de halogenopirimidinas aril eter; composicion pesticida; procedimiento de preparacion; compuestos intermediarios; y uso del compuesto como agente pesticida.
ES2052881T3 (es) Agentes reductores de la presion sanguinea.
ES2113127T3 (es) Derivado de androstenona.
BR0108871A (pt) Composto, processo de preparação de compostos, e, composição farmacêutica
ATE190838T1 (de) Injizierbare arzneizubereitungen enthaltend taxanderivate
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
CY1107899T1 (el) 6.αλφα., 9.αλφα. - διφθορο-17.αλφα.-(2-φουρανυλοανθρακοξυλικο) οξυ-11.βητα.-υδροξυ-16.αλφα.-μεθυλο-3-οξο-ανδροστα-1,4-διενιο-17-ανθρακοθειϊκο οξυ s-φθορομεθυλο εστερας ως αντιφλεγμονωδης παραγοντας
GT199900040A (es) Biciclo [2.2.1] heptanos y compuestos relacionados.
ES2176698T3 (es) Nuevos derivados de la eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
ES2128519T3 (es) Nuevas pirido-tiadiazinas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
DE69529998D1 (de) Glp-1 zusammensetzungen mit verlängerter wirkdauer
AU536920B2 (en) Hydroxypropyl-triazole derivatives and their use as antimycotic agents
DE69912983D1 (de) Wassermischbare pharmazeutische zusammensetzungen enthaltend paclitaxel
MX9604483A (es) Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
YU11401A (sh) Lokalne farmaceutske kompozicije koje sadrže nimesulid
ES2190429T3 (es) Benciliden-quinuclidinonas como agentes protectores contra el sol.
FI803264L (fi) 2-hydroxialkyl-3,4,5-trihydroxipiperidiner foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
BR9710373A (pt) Composição geradora de cor, compreendendo um agente contendo unidades de pirogalol, um sal de ferro (ii) e um ácido orgânico
SE8002831L (sv) Oxitetracyklinberedningar
ES2159054T3 (es) Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios.